Notable Analyst Rating Changes 11/3: (LC) (ITRI) (FINL) Upgraded; (SRCL) (FIT) (SKX) Downgraded

November 3, 2016 10:41 AM EDT

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

UPGRADES
Morgan Stanley upgrades Lending Club (NYSE: LC) from Equalweight to Overweight with a price target of $7.

Oppenheimer lifts Itron (Nasdaq: ITRI) from Perform to Outperform with a price target of $60.

Susquehanna raises Finish Line (Nasdaq: FINL) from Neutral to Positive with a price target of $23. Click Here for more color.

Raymond James boosts VMware (NYSE: VMW) from Market Perform to Outperform with a price target of $90.

For daily real-time Upgrades go to http://www.streetinsider.com/Upgrades

DOWNGRADES
Goldman Sachs downgraded Stericycle (Nasdaq: SRCL) from Neutral to Sell with a price target of $60.

Fitbit (NYSE: FIT) received several downgrades today:

  • Morgan Stanley from Overweight to Equalweight and moves its price target from $31 to $11.
  • Mizuho Securities from Outperform to Neutral with a price target of $9. Click Here for more color.
  • Piper Jaffray from Neutral to Underweight and moves its price target from $14 to $8.
  • Longbow Research from Buy to Neutral.
  • SunTrust Robinson Humphrey from Buy to Hold and moves its price target from $17 to $10. Click Here for more color.
  • Citi from Buy to Neutral.
  • BofAMerrill Lynchh from Buy to Underperform with a price target of $9.
  • Wedbush from Outperform to Neutral and moves its price target from $18 to $10. Click Here for more color.


B. Riley downgraded Skechers USA (NYSE: SKX) from Buy to Neutral.

Morgan Stanley downgraded Vitamin Shoppe (NYSE: VSI) from Overweight to Equalweight and moves price target from $32 to $26.

For daily real-time Downgrades go to http://www.streetinsider.com/downgrades

NEW COVERAGE
B. Riley initiates Viveve Medical (Nasdaq: VIVE) with a Buy rating and a price target of $8.

Aegis Capital assumes coverage on Cynosure (Nasdaq: CYNO) with a Buy rating and a price target of $60.

Credit Suisse begnins Vivint Solar (NYSE: VSLR) with a Neutral rating and a price target of $4.

Deutsche Bank starts Halozyme Therapeutics (Nasdaq: HALO) with a Buy rating and a price target of $12.

For daily real-time New Coverage go to http://www.streetinsider.com/New+Coverage

Visit our new Ratings Insider portal to get the most comprehensive and up-to-date analyst coverage on the Street.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Special Reports

Related Entities

Credit Suisse, Piper Jaffray, Deutsche Bank, Goldman Sachs, Citi, Raymond James, Morgan Stanley, Bank of America, B. Riley, SunTrust Robinson Humphrey, Longbow Research, Susquehanna International Group of Companies, Notable Analyst Rating Changes

Add Your Comment